{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:24Z","timestamp":1740108324518,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864"],"award-info":[{"award-number":["NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864","NSFC82003864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Sailing Program","award":["19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700"],"award-info":[{"award-number":["19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700","19YF1405700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00228-024-03674-w","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T07:02:43Z","timestamp":1710831763000},"page":"1029-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4"],"prefix":"10.1007","volume":"80","author":[{"given":"Tianye","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bicui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biyu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"3674_CR1","unstructured":"World Health Organization (2023) Hepatitis B. World Health Organization website. https:\/\/www.who.int\/zh\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed 18 Nov 2023"},{"key":"3674_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3389\/fimmu.2017.01142","volume":"8","author":"Y Xu","year":"2017","unstructured":"Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z (2017) Dynamic perturbations of CD4 and CD8 T cell receptor repertoires in chronic hepatitis B patients upon oral antiviral therapy. Front Immunol 8:1142. https:\/\/doi.org\/10.3389\/fimmu.2017.01142","journal-title":"Front Immunol"},{"issue":"23","key":"3674_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007064","volume":"96","author":"X Yang","year":"2017","unstructured":"Yang X, Li J, Liu J, Gao M, Zhou L, Lu W (2017) Relationship of Treg\/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: a longitudinal observational study. Medicine (Baltimore) 96(23):e7064. https:\/\/doi.org\/10.1097\/MD.0000000000007064","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3674_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/1744-9987.12839","volume":"24","author":"B Liu","year":"2020","unstructured":"Liu B, Shen B, Mei M, Li L, Wang X, Zhao H (2020) Potential effects of telbivudine versus entecavir on renal function in patients with chronic hepatitis B virus receiving Glucocorticoids Therapy. Ther Apher Dial 24(1):56\u201363. https:\/\/doi.org\/10.1111\/1744-9987.12839","journal-title":"Ther Apher Dial"},{"issue":"8","key":"3674_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237586","volume":"15","author":"HC Yu","year":"2020","unstructured":"Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH (2020) Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS ONE 15(8):e0237586. https:\/\/doi.org\/10.1371\/journal.pone.0237586","journal-title":"PLoS ONE"},{"issue":"1","key":"3674_CR6","doi-asserted-by":"publisher","first-page":"2029259","DOI":"10.1080\/21645515.2022.2029259","volume":"18","author":"Y Li","year":"2022","unstructured":"Li Y, Chen W, Jin C, Wang T, Yao T, Feng S, Wang B, Feng Y, Wang S (2022) Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine. Hum Vaccin Immunother 18(1):2029259. https:\/\/doi.org\/10.1080\/21645515.2022.2029259","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"3674_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MCG.0000000000001779","volume":"57","author":"H Jiang","year":"2023","unstructured":"Jiang H, Ye X, Chen C, Zhou G, Han G (2023) Efficacy and long-term safety of telbivudine usage during second or third trimester in hepatitis B surface antigen positive mothers with high viral load: a 10-year prospective study. J Clin Gastroenterol 57(4):423\u2013428. https:\/\/doi.org\/10.1097\/MCG.0000000000001779","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3674_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169444","volume":"12","author":"T Xing","year":"2017","unstructured":"Xing T, Xu H, Cao L, Ye M (2017) HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis. PLoS ONE 12(1):e0169444. https:\/\/doi.org\/10.1371\/journal.pone.0169444","journal-title":"PLoS ONE"},{"issue":"8","key":"3674_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14787210.2020.1760843","volume":"18","author":"J Geng","year":"2020","unstructured":"Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q, Yu H (2020) Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 18(8):823\u2013834. https:\/\/doi.org\/10.1080\/14787210.2020.1760843","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"3674_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00228-015-1978-9","volume":"72","author":"L Chen","year":"2016","unstructured":"Chen L, Cheng C, Chen B, Zhao Y, Zhang J, Wang B (2016) Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Eur J Clin Pharmacol 72(2):235\u2013241. https:\/\/doi.org\/10.1007\/s00228-015-1978-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3674_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1478-3231.2011.02490.x","volume":"31","author":"EJ Gane","year":"2011","unstructured":"Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C (2011) Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 31(5):676\u2013684. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02490.x","journal-title":"Liver Int"},{"issue":"9","key":"3674_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162760","volume":"11","author":"T Ambang","year":"2016","unstructured":"Ambang T, Tan JS, Ong S, Wong KT, Goh KJ (2016) Clinicopathological features of telbivudine-associated myopathy. PLoS ONE 11(9):e0162760. https:\/\/doi.org\/10.1371\/journal.pone.0162760","journal-title":"PLoS ONE"},{"issue":"1","key":"3674_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12876-018-0773-3","volume":"18","author":"Y Ying","year":"2018","unstructured":"Ying Y, Hu YK, Jin JL, Zhang JM, Zhang WH, Huang YX (2018) Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B. BMC Gastroenterol 18(1):45. https:\/\/doi.org\/10.1186\/s12876-018-0773-3","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"3674_CR14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1365-2893.2010.01412.x","volume":"18","author":"XJ Zou","year":"2011","unstructured":"Zou XJ, Jiang XQ, Tian DY (2011) Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat 18(12):892\u2013896. https:\/\/doi.org\/10.1111\/j.1365-2893.2010.01412.x","journal-title":"J Viral Hepat"},{"issue":"22","key":"3674_CR15","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.3748\/wjg.14.3549","volume":"14","author":"XS Zhang","year":"2008","unstructured":"Zhang XS, Jin R, Zhang SB, Tao ML (2008) Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 14(22):3549\u20133553. https:\/\/doi.org\/10.3748\/wjg.14.3549","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3674_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3988\/jcn.2023.19.1.52","volume":"19","author":"MY Lan","year":"2023","unstructured":"Lan MY, Lin HC, Hu TH, Chen SF, Chen CH, Chang YY, Chiu KW, Lin TK, Chen SS (2023) Telbivudine-induced myopathy: clinical features, histopathological characteristics, and risk factors. J Clin Neurol 19(1):52\u201359. https:\/\/doi.org\/10.3988\/jcn.2023.19.1.52","journal-title":"J Clin Neurol"},{"issue":"3","key":"3674_CR17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1128\/AAC.50.3.874-879.2006","volume":"50","author":"XJ Zhou","year":"2006","unstructured":"Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL (2006) Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 50(3):874\u2013879. https:\/\/doi.org\/10.1128\/AAC.50.3.874-879.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"3674_CR18","doi-asserted-by":"publisher","first-page":"3878796","DOI":"10.1155\/2023\/3878796","volume":"2023","author":"X Yin","year":"2023","unstructured":"Yin X, Jiang K, Zhou Z, Yu H, Yan D, He X, Yan S (2023) Prognostic and immunological potential of ribonucleotide reductase subunits in liver cancer. Oxid Med Cell Longev 2023:3878796. https:\/\/doi.org\/10.1155\/2023\/3878796","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"3674_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ana.26185","volume":"90","author":"C Lopez-Gomez","year":"2021","unstructured":"Lopez-Gomez C, Sanchez-Quintero MJ, Lee EJ, Kleiner G, Tadesse S, Xie J, Akman HO, Gao G, Hirano M (2021) Synergistic deoxynucleoside and gene therapies for thymidine kinase 2 deficiency. Ann Neurol 90(4):640\u2013652. https:\/\/doi.org\/10.1002\/ana.26185","journal-title":"Ann Neurol"},{"issue":"1","key":"3674_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12915-021-01155-5","volume":"19","author":"ML Lacombe","year":"2021","unstructured":"Lacombe ML, Lamarche F, De Wever O, Padilla-Benavides T, Carlson A, Khan I, Huna A, Vacher S, Calmel C, Desbourdes C et al (2021) The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor. BMC Biol 19(1):228. https:\/\/doi.org\/10.1186\/s12915-021-01155-5","journal-title":"BMC Biol"},{"issue":"3","key":"3674_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2217\/FVL-2016-0094","volume":"12","author":"J Long","year":"2017","unstructured":"Long J, Wang M, Chen B, Zhang J, Wang B (2017) Chronic hepatitis B a critical discussion. Future Virol 12(3):111\u2013117. https:\/\/doi.org\/10.2217\/FVL-2016-0094","journal-title":"Future Virol"},{"issue":"3","key":"3674_CR22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.kint.2018.10.019","volume":"95","author":"DY Li","year":"2019","unstructured":"Li DY, Yin WJ, Yi YH, Zhang BK, Zhao J, Zhu CN, Ma RR, Zhou LY, Xie YL, Wang JL, Zuo SR, Liu K, Hu C, Zhou G, Zuo XC (2019) Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population. Kidney Int 95(3):636\u2013646. https:\/\/doi.org\/10.1016\/j.kint.2018.10.019","journal-title":"Kidney Int"},{"issue":"4","key":"3674_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4140","volume":"32","author":"B Chen","year":"2018","unstructured":"Chen B, Chen L, Cheng C, Zhong M, Shi X, Zhang J, Wang B (2018) Determination of telbivudine in the plasma of chronic hepatitis B patients in long-term treatment by high-performance liquid chromatographic-tandem mass spectrometry. Biomed Chromatogr 32(4):e4140. https:\/\/doi.org\/10.1002\/bmc.4140","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"3674_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.cr.7290272","volume":"15","author":"YY Shi","year":"2005","unstructured":"Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15(2):97\u201398. https:\/\/doi.org\/10.1038\/sj.cr.7290272","journal-title":"Cell Res"},{"issue":"6","key":"3674_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0091270009333555","volume":"49","author":"XJ Zhou","year":"2009","unstructured":"Zhou XJ, Ke J, Sallas WM, Farrell C, Mayers DL, Pentikis HS (2009) Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment. J Clin Pharmacol 49(6):725\u2013734. https:\/\/doi.org\/10.1177\/0091270009333555","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3674_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","volume":"51","author":"RD Fleischer","year":"2009","unstructured":"Fleischer RD, Lok AS (2009) Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 51(4):787\u2013791. https:\/\/doi.org\/10.1016\/j.jhep.2009.06.011","journal-title":"J Hepatol"},{"issue":"17","key":"3674_CR27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJM199510263331702","volume":"333","author":"R McKenzie","year":"1995","unstructured":"McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C et al (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333(17):1099\u20131105. https:\/\/doi.org\/10.1056\/NEJM199510263331702","journal-title":"N Engl J Med"},{"issue":"11","key":"3674_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/jclinpath-2013-202069","volume":"67","author":"H Xu","year":"2014","unstructured":"Xu H, Wang Z, Zheng L, Zhang W, Lv H, Jin S, Yuan Y (2014) Lamivudine\/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol 67(11):999\u20131005. https:\/\/doi.org\/10.1136\/jclinpath-2013-202069","journal-title":"J Clin Pathol"},{"key":"3674_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110692","volume":"383","author":"W Yu","year":"2023","unstructured":"Yu W, Li Z, Wu W, Zhao D, Yan C, Lin P (2023) Insights into the mechanisms of telbivudine-induced myopathy associated with mitochondrial dysfunction. Chem Biol Interact 383:110692. https:\/\/doi.org\/10.1016\/j.cbi.2023.110692","journal-title":"Chem Biol Interact"},{"issue":"6","key":"3674_CR30","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/jcm10061249","volume":"10","author":"D Orsucci","year":"2021","unstructured":"Orsucci D, Caldarazzo Ienco E, Rossi A, Siciliano G, Mancuso M (2021) Mitochondrial syndromes revisited. J Clin Med 10(6):1249. https:\/\/doi.org\/10.3390\/jcm10061249","journal-title":"Clin Med"},{"key":"3674_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.bcp.2017.10.005","volume":"146","author":"L Jianfei","year":"2017","unstructured":"Jianfei L, Min W, Chunlai M, Bicui C, Jiming Z, Bin W (2017) The Ca2+\/CaMKK2 axis mediates the telbivudine induced upregulation of creatine kinase: implications for mechanism of antiviral nucleoside analogs\u2019 side effect. Biochem Pharmacol 146:224\u2013232. https:\/\/doi.org\/10.1016\/j.bcp.2017.10.005","journal-title":"Biochem Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03674-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:32:28Z","timestamp":1717731148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03674-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3674"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03674-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Helsinki Declaration and approved by the ethical committee of HuaShan Hospital. Informed consent was obtained from all study patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}